TJ 9

Drug Profile

TJ 9

Alternative Names: H09; Saiko-keishi-to; Sho-saiko-to; Shosaiko-toi; Shosaikoto-go-keishika-shakuyakuto; SST; TJ-9; Xiao-chai-hu-tang

Latest Information Update: 10 Aug 2015

Price : $50

At a glance

  • Originator Tsumura
  • Developer Janssen Pharmaceutical KK; Memorial Sloan-Kettering Cancer Center; Tsumura
  • Class Antiretrovirals; Herbal medicines
  • Mechanism of Action Immunomodulators; Immunostimulants; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; HIV infections
  • No development reported Hepatocellular carcinoma
  • Discontinued Diabetes mellitus

Most Recent Events

  • 10 Aug 2015 No recent reports on development identified - Phase-II for Hepatitis C in USA (PO)
  • 14 Dec 2012 No development reported - Phase-II for Hepatocellular carcinoma in USA (PO)
  • 22 Feb 2010 Phase-II development is ongoing for hepatitis C in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top